Lymph nodes are immunological meeting places, in which B cells, T cells, dendritic cells (DCs), plasma cells and macrophages congregate inside an encapsulated mesenchymal sponge that is created by a network of fibroblastic reticular cells (FRCs) and infiltrating lymphatics. The structure of the lymph node is crucial to its function, as it funnels antigens and antigen-presenting cells towards rare antigen-specific lymphocytes to maximize their chance of finding each other and of initiating an adaptive immune response. In this Review, we discuss the role of FRCs in facilitating this process.
FRCs are immunologically specialized myofibroblasts of mesenchymal origin [1] [2] [3] [4] [5] . They can be distinguished from other lymph node-resident cells by their expression of podoplanin (PDPN) and platelet-derived growth factor receptor-α (PDGFRα), and their lack of expression of CD31 and CD45. They express molecules common to many myofibroblasts, including desmin, vimentin, CD73, CD90, CD105, α-smooth muscle actin (αSMA) and the antigen recognized by the ER-TR7 antibody 1, 2 . Compared with dermal fibroblasts, FRCs also express a more immunologically focused gene signature that is markedly enriched in genes from antigen presentation and cytokine response pathways 2 . FRCs are likely to be functionally related to follicular dendritic cells (FDCs), but these uniquely specialized stromal cells of B cell follicles -which are required for high-affinity antibody generation and for the normal formation of germinal centres -have recently been discussed in depth 6 and thus are only briefly covered in this Review and only in the context of lymph nodes. FRCs are found in the lymph nodes, spleen, thymus and other lymphoid tissues, but lymph node-derived FRCs are the best studied and are the focus of this Review. FRCs comprise 20-50% of the non-haematopoietic compartment of lymph nodes 1, 7 . They form stellate cell-cell contacts to create a three-dimensional open network on which leukocytes migrate 4, 8 . FRCs also produce and ensheath a highly ordered, interconnected web of extracellular matrix (ECM) components, creating the conduit network, which rapidly transports soluble antigens and signalling molecules deep into the lymph node parenchyma 5, 9, 10 . Importantly, FRCs provide strength and flexibility to the lymph node, as well as imposing compartmentalization of B cells and T cells by directing leukocyte traffic through chemokine secretion 1, 3, 10 . Naive T cells and DCs are in constant contact with FRCs, migrating along the network and scanning each other for antigen-specific affinity 3, 4, 10 . This intimate contact gives FRCs the ability to fundamentally regulate adaptive immunity 10 . Recent advances in FRC biology have shown that the immunological effect of these cells extends beyond the lymph node. In this Review, we show that normal functioning of the FRC network is essential to immunological health. We describe the crucial molecular cues for FRC development and function, and we discuss the role of FRCs in the creation of the lymph node microenvironment, through interactions with B cells, T cells, DCs and high endothelial venules (HEVs). We discuss the systemic effect of these interactions by examining 
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In this Review, we focus on recent advances regarding the immunobiology of lymph node-derived FRCs, presenting an updated view of crucial checkpoints during their development and their dynamic control of lymph node expansion and contraction during infection. We highlight the robust effects of FRCs on systemic B cell and T cell responses, and we present an emerging view of FRCs as drivers of pathology following acute and chronic viral infections. Lastly, we review emerging therapeutic advances that harness the immunoregulatory properties of FRCs. 11 but is yet to be formally proven. In this section, we review evidence for a model in which dual progenitor cells contribute to the development of LTo cells. Newly reported developmental steps that induce the differentiation of FRC progenitor cells and FRCs are also discussed.
Lymphoid tissue organizer cells (LTo cells
)
Subsets of FRCs.
At least five subsets of FRCs have been described in the lymph nodes, which are defined by their location and their expression of functional markers (TABLE 1) . With the exception of FDCs, many studies have referred to these subsets collectively as FRCs and, unless the subset is identified in the primary source, we do the same in this Review. T cell zone reticular cells are very well described 1, 12 , followed by the marginal reticular cell subset, which can differentiate into lymph node FDCs 13 . Other subsets include resident and inducible B cell zone reticular cells that support B cell survival and follicle integrity, pericyte FRCs that strengthen the barrier function of HEVs, and FDCs that support germinal centres.
Molecular cues that drive lymph node stromal development. The molecular cues and the precise cell types that drive the development of lymph node mesenchymal stroma are still incompletely defined (FIG. 1) . A current model suggests that lymph node imprinting of the mesenchymal precursor cells from which FRCs derive occurs when neurons release retinoic acid 14 . In response to retinoic acid, local undifferentiated mesenchymal precursor cells release CXC-chemokine ligand 13 (CXCL13) to initiate the lymph node anlage 14 
.
More recent evidence reveals a second stream of mesenchymal precursor cells that migrate into the lymph nodes from adjacent adipose tissue. During embryo genesis and postnatally, pre-adipocytes can be recruited from these fat pads into the lymph nodes in a lymphotoxin-β receptor (LTβR)-dependent manner 15 , with a partial requirement for CXC-chemokine receptor 4 (CXCR4) 16 . Upon arrival in the lymph node, the pre-adipocytes differentiate into CXCL13 + early LTo cells. In adult mice, fat pad-derived stromal progenitor cells give rise to approximately 60% of FRCs 15 . The evidence suggests that both locally derived and distal adipose tissue-derived precursor cells are likely to contribute to lymph node mesenchyme formation [14] [15] [16] [17] . CXCL13 attracts haematopoietic drivers of lymph node development known as lymphoid tissue inducer cells (LTi cells; a subset of group 3 innate lymphoid cells (ILCs)), which express CXCR5 (REF. 18 ). The attraction of group 3 ILCs is a crucial checkpoint in lymph node development 19 . However, Cxcl13 −/− mice do not have a complete block in lymph node development; mesenteric and cervical lymph nodes develop but cutaneous lymph nodes are lacking in these mice 20 . Mice deficient for both CXCL13 and interleukin-7 receptor subunit-α (IL-7Rα) lack all lymph nodes, which reveals a contributive role for IL-7-mediated signalling in lymph node development 18 . Similarly, mice deficient for CC-chemokine receptor 7 (CCR7) and CXCL13 have a greater loss of lymph nodes than mice deficient for CXCL13 alone 18 . b | Lymphotoxin-β receptor (LTβR) signalling is a molecular switch that drives lymph node stromal cell development at the expense of adipocyte development 15 . The migration of pre-adipocytes to the lymph node site is augmented by CXC-chemokine receptor 4 (CXCR4) 16 . On arrival, these cells upregulate CXCL13 expression to become early LTo cell-committed stromal precursor cells. c | Early LTo cells differentiate into primed LTo cells when they begin to express low levels of intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) 79 . The signals required for this differentiation step involve CXCR5, CC-chemokine receptor 7 (CCR7), CXCL13 and interleukin-7 receptor (IL-7R) 18, 20 . Mice with blocks in this signalling pathway develop lymph node anlagen and early LTo cells but not lymph nodes 11, 17, 19 . e | It is hypothesized that early FRC precursor cells develop directly from differentiated LTo cells, but this has not been formally shown. Interactions between podoplanin (PDPN) and C-type lectin domain family 1 member B (commonly known as CLEC2) are crucial checkpoints for FRC development 24, 25 , as Pdpn −/− and Clec1b −/− mice develop lymph node anlagen but no lymph nodes. It is unclear exactly where this block lies, but it is before the development of FRC precursor cells. The source of CLEC2 is undefined. f | The development of mature FRCs from immature FRC precursor cells requires lymphotoxin signalling. Lymph nodes lacking the nuclear factor-κB2 (NF-κB2) signalling pathway (Relb −/− , Nfkb2 −/− and IκB kinase-α (Ikka) −/− lymph nodes) are present, but they are hypoplastic and B cell deficient 81, 82 , which indicates that the canonical NF-κB signalling pathway may partly compensate for loss of LTβR. The loss of LTβR from LTo cells at the point of CCL19 upregulation facilitates the development of lymph nodes and FRC precursor cells but blocks late-stage FRC development, thus identifying the immediate precursors of FRCs 26 . In humans and some primates 27 , but not in mice 8 , CD4
+ T cells are a crucial source of LTβR ligands. g | Follicular dendritic cells are capable of developing from a population of clonally expanded marginal reticular cells 6, 13 . BAFF, B cell-activating factor; LTα, lymphotoxin-α; MADCAM1, mucosal vascular addressin cell adhesion molecule 1; MFGE8, lactadherin; Raldh2, retinal dehydrogenase 2; RANKL, RANK ligand.
After specification of the lymph node anlage, receptor activator of NF-κB ligand (RANKL; also known as TNFSF11) signals through RANK expressed by group 3 ILCs. The origin of RANKL is hypothesized to be group 3 ILCs themselves, through trans-signalling as they cluster together 17, 21 . The RANK signal induces LTi cells to upregulate expression of lymphotoxin α1β2 (LTα1β2) 21 . Upregulation of LTα1β2 can also be induced by IL-7, which can substitute for RANKL in early lymph node genesis 18, 22 . For both types of stromal precursor cell (locally derived cells and pre-adipocyte cells), LTβR signalling is a crucial checkpoint that drives differentiation into LTo cells, although the signalling cell type and the required timing are still under investigation. Expression of LTβR by the endothelium partly contributes to this process -in VE-cadherin (Cdh5)-Cre × Ltbr fl/fl mice, 20-45% of peripheral lymph nodes fail to develop 23 , such that the mice lack brachial and inguinal lymph nodes, whereas mesenteric lymph nodes develop normally 23 . The cells that are responsible for driving LTβR-dependent development of the remaining 55-80% of lymph nodes are presumably mesenchymal LTo cells, but this has not been experimentally proven. LTo cells express LTβR, PDPN and CXCL13, and undergo LTβR-dependent upregulation of expression of mucosal vascular addressin cell adhesion molecule 1 (MADCAM1), CCL19, CCL21, intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) 11 . This expression profile attracts a new wave of group 3 ILCs, thereby increasing the provision of LTβR ligands and group 3 ILC-attracting chemokines, which enables the haemato poietic compartment and the mesenchyme to develop in parallel.
Lymph node stromal development is also dependent on poorly defined interactions between PDPN and its ligand C-type lectin domain family 1 member B (commonly known as CLEC2; encoded by Clec1b), as Pdpn −/− mice and Clec1b −/− mice have lymph node anlagen but do not develop lymph nodes 24, 25 . Mice with platelet-restricted deletion of Clec1b have lymph nodes 24 , so the crucial source of CLEC2 for lymph node development is still unconfirmed.
Maturation and maintenance of FRCs. LTβR signalling is also required at later stages for the final maturation of FRCs. Immediate precursors of FRCs were found in mice in which LTβR signals were conditionally blocked in CCL19 + cells -in other words, in and downstream of differentiated LTo cells 26 . The lymph nodes in these mice developed a mesenchymal network and a conduit system, but they had decreased lymph node-wide expression of CCL19, CCL21 and IL-7, which are crucial molecules for crosstalk with lymphocytes and DCs 26 . However, distinct B and T cell zones were maintained in these lymph nodes 26 , so it is possible that low levels of chemokines are sufficient for lymphocyte organization.
Studies in primates showed that depletion of CD4 + T cells, but not of CD8 + T cells, ablated the FRC network, reduced the distinction between B and T cell zones, and decreased IL-7 staining 27 . Naive CD4 + T cells were the major source of LTα1β2 in these lymph nodes 27 , although the molecular mechanism of FRC loss remains to be determined. Interestingly, mouse T cell zone reticular cells and marginal reticular cells do not seem to require B cells and T cells for development at normal frequencies 8, 28, 29 
Structural organization of lymph nodes by FRCs
Throughout postnatal life, FRCs keep lymph nodes in a response-ready state through continual inter actions with constituent leukocyte populations and other paren chymal cells (FIG. 2) . These interactions, which are discussed below, ensure that lymphocytes are poised to respond to antigen and inflammation by generating an adaptive immune response.
FRCs attract and maintain T cells. It is well described that paracortical T cell zone reticular cells secrete CCL19 and CCL21 to keep CCR7 + IL-7R + naive T cells and DCs moving throughout the FRC network in search of antigen-specific interactions but to confine them mainly to the paracortex 1, 4, 10 . FRCs also secrete IL-7, which promotes the survival of T cells and DCs 1,2 . Accordingly, deletion of FRCs depletes naive T cells from lymph nodes and impairs their recruitment to these structures 33 .
FRCs support B cell survival. New lines of rapidly converging evidence also support a role for FRCs in the maintenance of B cells. It was initially reported that cultured FRCs promote the survival of malignant B cells, which otherwise rapidly die in culture 34 . Moreover, FRCs can transcribe the B cell growth factor B cell-activating factor (Baff; also known as Tnfsf13b) and the B cell chemo attractant Cxcl13 (REFS 2,30), which suggests a role for FRCs in B cell maintenance and attraction; by contrast, FDC ablation did not induce the loss of B cells from primary follicles 35 . Fate-mapping showed that an intrafollicular subset of CD21 − FRCs becomes enveloped by expanding B cell follicles during infection. These FRCs rapidly upregulate CXCL13 protein expression during infection through crosstalk with B cells to control follicular boundaries 30 , in effect differentiating into a type of B cell zone reticular cell. Most recently, in vivo FRC depletion experiments 33, 36 , which have been mechanistically dissected using in vitro co-cultures 36 , showed that B cell zone reticular cells resident within the B cell follicle promote B cell survival through the provision of BAFF and control the boundaries of primary B cell follicles 36 . Importantly, deletion of FRCs in these models did not destroy the lymph node or deplete FDCs 33, 36 or activated T cells 33 .
FRCs maintain DCs and promote their migration. The effect of FRC depletion on DCs has also been studied 33 . Both conventional DCs (CD8α + and CD8α − ) and migratory DCs were markedly depleted when FRCs . Paracortical FRCs also create the conduit network -which conveys small molecules from afferent lymphatics towards the paracortex and high endothelial venules (HEVs) 5,9 -and secrete the T cell pro-survival factor interleukin-7 (IL-7) . When leukocytes move into lymph nodes via HEVs, PDPN expressed by FRCs ligates CLEC2 expressed by the small number of accompanying platelets. This signal mediates sphingosine-1-phosphate (S1P) release from the platelet surface, which signals to HEVs to upregulate the junctions between cells formed by VE-cadherin 40 . BAFFR, BAFF receptor (also known as TNFRSF13C); IL-7R, IL-7 receptor; S1PR1, S1P receptor 1; TCR, T cell receptor. were absent from lymph nodes 33 . DC migration is an active process, requiring amoeboid movement and a scaffold on which to crawl 37 . Recent advances have shown that, mechanistically, PDPN is a key molecule in many aspects of FRC function, including promoting DC motility 38 . PDPN interacts with CLEC2, which is upregulated by antigen-bearing DCs, and this interaction regulates the formation of membrane protrusions and motility in DCs 38 .
FRCs control HEV permeability. FRCs control lymph node endothelial cell proliferation through vascular endothelial growth factor (VEGF) secretion, in an LTβR-dependent manner 39 . HEVs carry out two seemingly contradictory roles; they must enable lymphocyte trafficking in and out of lymph nodes but maintain a barrier function to prevent blood components from leaking into lymphoid organs 40 . New data show that platelets, which express CLEC2, permeate venules and contact perivascular PDPN + FRCs surrounding the HEVs. The interaction of CLEC2 with PDPN causes the release of stored sphingosine-1-phosphate (S1P) from platelets, which signals through the S1P receptor 1 (S1PR1) on HEVs to drive upregulation of VE-cadherin expression, thereby reinforcing the cell-cell junctions that are integral to HEV barrier function 40 . This continuous interaction between platelets and FRCs prevents cellular and acellular components of the blood from indiscriminately leaking into lymph nodes.
FRCs censor effector T cell functions
Despite being sites in which immune responses are robustly initiated, there is evidence that lymph nodes are also sites of immune privilege, in which effector T cell responses are censored [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . FRCs contribute to the maintenance of T cell tolerance in three ways, which are discussed below.
FRCs mediate deletional tolerance. Early studies noted that T cells with affinity for peptide-MHC complexes presented by lymph node stromal cells became activated but were swiftly lost from the peripheral T cell pool [41] [42] [43] [44] . It was later shown that FRCs express tissue-specific self antigens native to a range of peripheral tissues 45, 46 and can directly present these antigens to CD8 + T cells for tolerance induction 45 . FRCs do not express autoimmune regulator (AIRE) 45, 46 , but they do express an AIRE-like molecule known as deformed epidermal autoregulatory factor 1 homologue (DEAF1), which regulates the expression of at least some self antigens that are relevant to the development of autoimmunity 44, 45 . Accordingly, the expression of peripheral tissue-restricted antigens by FRCs prevents autoimmunity in animal models by directly deleting autoreactive T cell clones 41, 43, 45 . This property is shared by lymphatic endothelial cells in the lymph nodes 46 , although each cell type seems to express a different range of antigens 45, 46 . Strikingly, in a model of chronic versus acute viral infection, direct infection of FRCs (which implies the presentation of viral peptides by MHC class I molecules on FRCs) was associated with inability to clear the virus and with the upregulation of programmed cell death protein 1 ligand 1 (PDL1) expression by the FRCs 47 . PDL1 expression was associated with the acquisition of an exhausted phenotype by responding CD8 + T cells, which prevented the lymph node stroma from incurring damage as a result of immunopathology 47 .
FRCs suppress effector T cell proliferation. As a second method of tolerance induction, FRCs enable T cell activation within lymph nodes but suppress effector T cell responses [48] [49] [50] . The mechanism is surprisingly generic. In vitro evidence indicates that any T cell, regardless of specificity, that begins producing interferon-γ (IFNγ) while crawling on an FRC is likely to have its proliferative capacity dampened through the absorption of FRC-generated nitric oxide [48] [49] [50] . Given that T cell movement correlates highly (93%) with the presence of an adjacent FRC fibre 4 , this is likely to be a fundamental mechanism that prevents T cells from acquiring effector functions within lymph nodes. In addition, FRCs can acquire intact peptide-MHC class II complexes from DCs, which in turn decreases the proliferation and the survival of antigen-specific CD4 + T cells 51 . It is important to note that this suppressive function of FRCs does not seem to impair systemic immune responses; in fact, loss of FRCs is associated with impaired systemic T cell-mediated immunity 33, 36, 53 . These observations are discussed in detail below.
FRCs support regulatory T cells. FRCs may also constrain effector T cells through effects on regulatory T (T Reg ) cells. Several studies have shown that FRCs express MHC class II molecules
2,51,52 . Furthermore, FRCs have the ability to process and to present antigen as shown by their expression of molecules from the MHC class II antigen processing and presentation pathway: namely, the invariant chain CD74; lysosomeassociated membrane glycoprotein 1 (LAMP1; also known as CD107a), which marks endosomes in which peptides are processed and loaded onto MHC class II molecules; and the molecular chaperone H2DM, which catalyses peptide loading onto MHC class II molecules 52 . In a lymph node stromal cell transplant model, the homeostatic proliferation of CD4 + forkhead box protein P3 (FOXP3) + T Reg cells required MHC class II expression on non-haematopoietic stromal cells. Using lymph node transplants from K14-OVA transgenic mice to monitor the antigen-specific T cell response to stromal cell expression of ovalbumin (OVA), there was an increased proportion of OVA-specific T Reg cells even in distal lymph nodes 52 . However, within the stromal cell population in lymph nodes, both FRCs and endothelial cells expressed OVA in this model 52 , so it has not yet been definitively shown that FRCs mediate this effect on T Reg cells. In a separate study, lymph node stromal cell transplants were used to show that mesenteric and coeliac lymph node stromal cells, but not cutaneous lymph node stromal cells, promote T Reg cell induction in a manner dependent on DCs 54 . Again, the results are suggestive of an FRC-dependent effect, although the mechanism is yet to be established.
Ezrin, radixin and moesin family proteins (ERM family proteins). Proteins that link the plasma membrane to the actin cytoskeleton. They are involved in cell adhesion, contraction and cortical morphogenesis.
Why are FRCs immunosuppressive?
A current theory is that the antigen presentation and T cell deletion functions of FRCs evolved to prevent autoimmunity, whereas T cell-suppressive mechanisms may have evolved to prevent damage to the infrastructure of the lymph node during an acutely inflammatory immune response, by supporting T cell egress and acquisition of effector functions external to the lymph node, rather than within it 10, 55 . Accordingly, suppressed T cells show reduced expression of the effector molecule IFNγ, and the survival of target cells as measured in cytotoxicity assays seems to be higher in the presence of suppressed T cells compared with non-suppressed T cells 49 . As discussed below, the maintenance of a suppressive environment within lymph nodes evidently does not prevent T cells that are activated in the presence of FRCs from initiating a robust systemic immune response 26, 33, 36 .
FRCs respond dynamically to infection
As we have described, in the absence of infection, FRCs help to keep lymph nodes in a state of self-tolerant readiness. However, once an adaptive immune response is initiated, FRCs undergo dynamic changes.
FRCs mediate lymph node flexibility.
A hallmark of the initiation of an adaptive immune response is the rapid expansion of lymph nodes to accommodate the trapping of naive lymphocytes, followed by a return to their homeostatic size as lymphocyte populations egress and contract. New studies place FRCs at the centre of lymph node hypertrophy and resolution 29, [56] [57] [58] (FIG. 3) .
Under homeostatic conditions, PDPN regulates constant actomyosin contractility of FRCs, which provides physical tension throughout the FRC network 56, 57 . This is achieved by steady-state signalling through ezrin, radixin and moesin family proteins (ERM family proteins) that link the cell membrane to the underlying actin network 56, 57 . In PDPN-overexpressing NIH-3T3 fibroblasts, phosphorylated ezrin was shown to accumulate at the cell cortex and to colocalize with PDPN 56 . The same cells transfected with a non-phosphorylatable ezrin mutant were non-contractile. Contractile force is driven by RHOA signalling, which regulates myosin II-mediated actin contractility through RHOassociated protein kinase (ROCK) 56 . In consequence, when PDPN expression is knocked down or PDPN is aggregated and inhibited by binding CLEC2, ezrin Nature Reviews | Immunology + fibroblastic reticular cells (FRCs) form an interconnected tensile network that maintains lymph node size. b | In an acute immune response, driven by inflammatory cues, the expression of C-type lectin domain family 1 member B (commonly known as CLEC2) is upregulated by both lymph node-resident and infiltrating migratory dendritic cells (DCs) 38, 83 . CLEC2 inhibits PDPN-driven actomyosin contractility of FRCs, resulting in FRC elongation and reduced lymph node tension, which enables rapid organ expansion in the absence of stromal cell proliferation 56, 57 . c | Acute responses also trigger FRC proliferation and/or the recruitment of FRC precursor cells to restore FRC to T cell ratios in the face of higher T cell numbers 29, [56] [57] [58] . d | Following acute damage to the FRC network, FRCs upregulate interleukin-7 (IL-7) production to activate group 3 innate lymphoid cells (ILCs), which help to regenerate and to rebuild the lymph node to repair damage 66, 74 . During chronic infections, such as with HIV, the resolution of damage may take years or may not occur at all 69, 70 . IL-7R, IL-7 receptor; LTα1β2, lymphotoxin α1β2; RANKL, receptor activator of NF-κB ligand. is uncoupled from PDPN and RHOA activity is rapidly inhibited. Less than a minute following CLEC2 binding to PDPN, RHOA activity is lost and RAC1 activity begins to gradually increase 56 . In response to inflammation, CLEC2 on resident and infiltrating activated DCs bound PDPN on FRCs and inhibited PDPN-mediated FRC contractility by clustering and partitioning PDPN molecules within lipid rafts 56, 59 , which uncoupled PDPN from ERM proteins and RHOA activity. The FRCs were then able to elongate, which released the tension of the FRC network and rendered it permissive to stretching 56 . This PDPN-dependent regulation of FRC contractility was also described in another study showing that directly inhibiting PDPN using targeted antibodies results in loss of tension throughout the FRC network 57 . As lymphocytes infiltrate the lymph nodes and proliferate, lymph nodes are therefore given the flexibility to accommodate the developing immune response without compromising the structural integrity of the stromal network 56, 57 .
Ccl19-Cre
FRCs proliferate during infection. The FRC network is capable of considerable proliferation in response to infection or lymph node inflammation 29, 56, 57 . It is therefore likely that cell proliferation, in addition to actomyosin contractility, contributes to the ability of FRCs to accommodate lymph node expansion. The time taken for FRCs to proliferate seems to depend on the stimulus used, ranging from 24 hours (for lipopolysaccharide 57 ) or 40 hours (for OVA in a mineral oil adjuvant 29 ) to 12 days (for OVA in complete Freund's adjuvant 56 ) or, in an analysis of a lone time point, 19 days (for Leishmania major 29 ). The signals that control FRC proliferation are still unclear. One study reported that access to T cells and DCs is important 58 , whereas another study proposed that the effects of DCs are indirect and that the trapping of naive T cells is an early trigger for growth and remodelling of the FRC network 29 . The same study reported that provision of LTβR ligands augmented a later stage of FRC proliferation, through a poorly defined mechanism that is independent of LTi cells, B cells and T cells 29 . RANKL may be an additional stimulus for FRC proliferation, as lymph nodes from transgenic mice that overproduced this protein were hyperproliferative, with increased numbers of RANK + FRCs and greater levels of production of the FRC-associated molecules CXCL13, CCL19, MADCAM1 and VCAM1 (REF. 60 ). In wild-type mice, activated T cells are a prominent source of RANKL 60 . As FRCs experience marked changes in mechanical strain during the initial phases of lymph node expansion that result from trapping of naive B cells and T cells, mechanical signals might be a trigger for FRC clonal expansion in situ 29, 56, 57 . Accordingly, PDPN inhibition induces both FRC elongation and proliferation 56, 57 , which would support a model in which stretching of FRCs gives rise to reactive proliferation. In at least two models of inflammation, FRC stretching occurred before proliferation 56, 29 . Although the evidence is as yet circumstantial, there is a precedent for this type of mechanism operating in lung parenchymal cells 61 .
The identification of progenitor or proliferative intermediate (transit-amplifying) cell types that might contribute to FRC proliferation is still in its infancy. Two studies report that adipocyte progenitor cells can contribute to the mesenchymal network in adult mice 15, 16 . Their influx into lymph nodes increased in inflammatory conditions 16 , and the adipocyte progenitor cells differentiated into T cell zone reticular cells and marginal reticular cells in reaggregate grafts 15 . It is equally possible that FRCs or their progenitors may proliferate in situ.
Loss of FRCs impairs systemic immune responses.
The effects of the FRC response to infection extend beyond the lymph node. A requirement for FRCs in the systemic generation of effector B cells and T cells and the normal initiation of both humoral and cellmediated immunity has recently been discovered. A model of systemic lymphocytic choriomeningitis virus (LCMV) infection (using the acute WE strain, which is controlled by CD8 + T cells) was used to test the requirement for mature, immunocompetent FRCs in Ccl19-Cre × Ltbr fl/fl mice 26 , which develop a mesenchymal network expressing abnormally low levels of PDPN, CCL19, CCL21 and IL-7. The lymph nodes of these mice have a 60-70% depletion of B cells, T cells, DCs and macrophages. Control mice cleared the virus by day 10 post infection, whereas Ccl19-Cre × Ltbr fl/fl mice could not clear the infection. In addition, localized mouse hepatitis virus infection -which requires a cervical lymph node-generated adaptive immune response for resolution, involving plasmacytoid DCs and CD4 + and CD8 + T cells -was unresolved 10 days after infection in Ccl19-Cre × Ltbr fl/fl mice, in contrast to controls 26 . Similar results have been obtained from two studies using mice that enable the temporal control of FRC deletion. One study selectively depleted FRCs using diphtheria toxin receptor (DTR) expression driven by fibroblast activation protein-α 33 . Mice receiving diphtheria toxin were unable to mount an effective immune response against influenza virus. This systemic effect resulted from a loss of naive B cells and T cells and DCs from lymph nodes, because the depletion of FRCs during active influenza virus infection had no effect on the magnitude of the immune response or on the presence or the function of activated B cells and T cells in lung-draining lymph nodes 33 . Another study immunized Ccl19-Cre × iDTR mice with a nonreplicative influenza A virus mutant expressing the OT-II epitope 36 . OT-II CD4 + T cells did not proliferate and did not have an activated phenotype in mice in which FRCs had been depleted before immunization 36 . The role of B cell zone reticular cells in the promotion of B cell survival has raised questions regarding the role of FRCs in generating a humoral immune response. It has now been shown that the initiation of IgG and IgA humoral immune responses to subcutaneous and oral antigens, respectively, is impaired in a natural graft-versus-host disease (GVHD) model of FRC elimination 53 .
Taken together, these studies show that the immunoregulatory effects of FRCs are of systemic relevance in generating cytotoxic T cell and T helper cell responses and humoral immunity. Future studies may seek to delineate the roles of FRCs in the lymph nodes versus the spleen, and in peripheral versus mesenteric lymph nodes, in the control of site-specific infections or in the promotion of cytotoxicity versus tolerance induction.
FRC-associated pathology
As discussed, FRCs regulate immune responses through their effects on the survival, migration and function of leukocytes, and their regulation of lymph node microenvironmental structure and lymph node size. As many of these functions are unique to FRCs, damage to these cells has detrimental outcomes for immunity.
FRCs are direct targets of virus infection. Several clinically important human pathogens directly infect FRCs, with systemic consequences. Ebola, Lassa and Marburg viruses -which cause high-mortality haemorrhagic fevers -all induce destruction of FRCs and the conduit network, which correlates with the loss of clearly distinguished B and T cell zones from the lymph nodes and spleen, as well as increased fibrosis [62] [63] [64] . Studies in rhesus macaques have shown that FRCs are directly infected by, and are a very early target of, Ebola virus and that lymph nodes are a site of considerable viral replication 63, 64 . Accordingly, a prominent hypothesis is that FRC infection assists in the production and dissemination of Ebola virions within lymphoid tissues 64 . The complete destruction of lymphoid tissues was among the extensive pathologies caused by Ebola virus in rhesus macaques 63 . FRCs are also efficiently infected by LCMV 47, 65, 66 , for which the availability of mouse models has enabled some mechanistic dissection. The ability of the immune system to clear LCMV negatively correlates with the propensity of the virus to infect FRCs. Infected FRCs upregulated their expression of PDL1, which is a protein associated with T cell exhaustion 47 . This did not affect antiviral CD8 + T cell priming, but it slowed both viral clearance and the onset of fatal immunopathology 67 . Infected FRCs were nonetheless efficiently destroyed by virus-specific cytotoxic T cells 65, 66 , which crippled the immune response to new antigens 66 .
FRC-mediated lymph node fibrosis causes immunodeficiency. FRCs help the lymph node to recover from acute infection by upregulating IL-7 expression, but chronic inflammation damages FRCs and, partly through these effects, impairs systemic immunity. During prolonged inflammation, T Reg cells upregulate expression of transforming growth factor-β1 (TGFβ1), which suppresses prolonged immune activation within lymph nodes in a beneficial manner but is also an important cause of FRC pathology [68] [69] [70] . In chronic HIV-1 and simian immunodeficiency virus (SIV) infection models, using rhesus macaques, the T Reg cell response produces high levels of TGFβ1. This stimulates the TGFβ receptor 2 (TGFβR2) signalling pathway in FRCs, driving increased collagen synthesis.
Secreted collagen accumulates around FRCs to the extent that naive lymphocytes die as they lose complete contact with FRCs and are unable to access their IL-7 output [68] [69] [70] [71] ( FIG. 4) . High levels of CD4 + T cell apoptosis in HIV-positive patients were previously assumed to occur as a result of direct infection of T cells and prolonged inflammation, but lymph node dysfunction driven by FRCs is now believed to be a major contributor to the T cell loss 27, [68] [69] [70] .
Loss of CD4
+ T cells (and hence of lymphotoxin production) deprives FRCs of the LTβR signals that are required for their maintenance. Administration of a CD4 + T cell-depleting antibody to rhesus macaques reduces the provision of LTβR ligands and depletes FRCs, which in turn induces the depletion of naive CD8 + T cells, thus creating a negative feedback loop and broad immuno suppression 27, 69 . Importantly, this finding is mirrored in HIV-positive and chemotherapy-treated patients, for whom the loss of CD4 + T cells is also associated with FRC and FDC depletion 27 . Prolonged T cell immunodeficiency is a major clinical issue after chemotherapy or irradiation, and it persists in 15-40% of treated HIV-positive patients, despite undetectable viral load 72, 73 .
FRCs are targets of allogeneic attack during GVHD.
It was recently reported that FRCs are an early target of GVHD-mediated attack in major and minor MHCmismatched animal transplant models 53 . Mice developed fibrotic lymph nodes and suffered an irreversible (>100 days) loss of the lymph node microenvironment, including loss of HEVs, of B and T cellularity, and of systemic humoral immunity 53 . Inherent in these observations is the idea that damage to the FRC network may hamper the ability of FRCs to promote immune recovery by providing new niches for naive B cells and T cells. As such, attempting to reverse lymph node fibrosis is an active area of research.
Therapeutic targeting of FRCs
Given the varied fundamental effects of FRCs on systemic immunity, there are several proposed therapeutic interventions seeking to target, exploit or replicate the immunoregulatory functions of FRCs.
FRCs drive lymph node recovery. After damage to the lymph node microenvironment -through acute infection, hypoxia or immunodepletion -FRCs are key regulators of lymph node re-establishment and remodelling 66, 74 , which makes them an attractive therapeutic target. FRCs respond to viral damage and hypoxia by upregulating IL-7 expression to promote the survival of group 3 ILCs 74 , which in turn drive LTβR-dependent rebuilding of the lymph node, similarly to lymph node development during embryogenesis 66, 74 . How FRCs sense this damage is unknown. Lymph node repair did not occur when IL-7 + stromal cells were depleted 74 . This finding was supported by research in HIV-positive patients, which found that loss of IL-7 + FRCs, which occurred as a result of fibrosis, was associated with prolonged immunodeficiency despite undetectable viral load 68, 69 . As such, the use of drugs to reduce stromal fibrosis has been proposed and preclinically tested (discussed below).
The irreversible loss of FRCs as a result of GVHD also resulted in prolonged humoral immunodeficiency, which persisted despite successful haematopoietic reconstitution 53 . The ability to restore FRCs or to prevent damage to them could therefore yield important clinical benefits.
Reduction of lymph node fibrosis. Antifibrotic drugs have been proposed to reduce lymph node fibrosis mediated by FRCs in response to HIV-1 infection 69 . Pirfenidone (5-methyl-1-phenylpyridin-2-one) targets the TGFβ1 pathway, with the aim of reducing extracellular matrix production by FRCs. Administration of pirfenidone in vitro reduced phosphorylation of SMAD2 and SMAD3 (signalling downstream of TGFβR) and the production of type I collagen by FRCs, in a dose-dependent manner 70 . In vivo administration of pirfenidone with antiretroviral therapy (ART) to SIV-infected rhesus macaques prevented the loss of desmin + FRCs, reduced the deposition of type I collagen and fibronectin in T cell zones of lymph nodes, and increased systemic CD4 + T cell numbers compared with ART alone 70 . Pirfenidone did not block TGFβ1 production but did inhibit the phosphorylation of SMAD2 and SMAD3 (REF. 70 ). These data support further clinical testing of the use of antifibrotic drugs in HIV-1 infection, to hasten T cell recovery after ART commences by decreasing FRC-mediated lymph node fibrosis and thereby slow or reduce the progression to AIDS. 
PDL1) expression by FRCs and, we speculate, may also involve other known suppressive pathways such as the release of nitric oxide, which is produced in response to interferon-γ (IFNγ) secreted by T cells. FRCs slow viral clearance through their use of such T cell-suppressive mechanisms. However, eventually infected FRCs are destroyed with high efficiency, which disrupts lymph node architecture and function, causing systemic lymphopenia and crippling the immune response to new antigens 47, 69, 70 . b | During chronic infection, the expansion of regulatory T (T Reg ) cell populations results in increased output of immunosuppressive transforming growth factor-β (TGFβ). This signals to FRCs to increase their collagen output, causing lymph node fibrosis. T cell access to the FRC-produced survival factor interleukin-7 (IL-7) is impeded. Loss of T cells concomitantly reduces the access of FRCs to lymphotoxin α1β2 (LTα1β2), which signals through LTβ receptor (LTβR). Hence, both FRCs and T cells are lost. This causes systemic, long-term lymphopenia and the loss of lymph node architecture and the conduit system 27, [68] [69] [70] . IFNγR, IFNγ receptor; IL-7R, IL-7 receptor; PD1, programmed cell death protein 1; TCR, T cell receptor; TGFβR2, TGFβ receptor 2. Recombinant IL-7 therapy to boost T cell numbers. Administration of recombinant human IL-7 to expand and support naive and effector memory T cells is also being trialled in immunodepleted or immuno deficient patients 75 . Beyond direct effects on T cells, IL-7 may assist in rebuilding atrophic lymph nodes by supporting group 3 ILCs, which in turn may support the development of LTo cells and the restoration of the lymph node architecture. Phase I and II trials are in varying stages of completion (ClinicalTrials.gov identifiers: NCT00105417, NCT02231853, NCT00477321, NCT00684008, NCT01881867, and others).
FRCs as an anti-inflammatory cell therapy. FRCs have also been administered as a cell therapy to animal models of sepsis and acute endotoxaemia. They significantly reduced mortality when administered as a single dose 4-16 hours after the septic insult 76 . FRCs in this model decreased the level of pro-inflammatory cytokines in the serum and at the site of initial infection, and decreased bacterial counts in the blood, in a mechanism dependent on FRC-mediated synthesis of the antibacterial and immunomodulatory molecule nitric oxide 76 . FRCs did not engraft long-term. Stromal cell-based therapies have gained considerable clinical attention in recent years for their ability to contribute to tissue healing and to decrease inflammation (reviewed in REF. 77 ). A distinct advantage over traditional single-molecule pharmaceuticals is that these cells can respond dynamically to inflammatory stimuli, thereby having effects on multiple molecules or pathways 76, 77 . It will be interesting to see whether human FRCs have similar efficacy in relevant models and whether FRCs may have therapeutic efficacy in other inflammatory diseases.
Conclusion and future directions
In recent years, FRCs have been found to have effects on all aspects of adaptive immunity. Their role as a physical support for leukocytes is well described but major findings continue to emerge. FRCs attract, retain and spatially organize naive lymphocytes by secreting chemokines and cytokines that support the growth, function and survival of other cell populations within the lymph node. FRCs also function as specialized pericytes that control HEV permeability. New findings show that FRC cytoskeletal tension controls lymph node size and flexibility. FRCs also remodel damaged lymphoid organs following the resolution of the infection, a process that is incomplete during chronic infection, resulting in immuno deficiency. Many unanswered questions remain
. Further study into FRCs may yield therapeutic solutions to the problems of chronic inflammation and lymphocyte activation.
